BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist 2019;24:e662-70. [PMID: 30651397 DOI: 10.1634/theoncologist.2018-0236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Oleinikov K, Korach A, Planer D, Gilon D, Grozinsky-Glasberg S. Update in carcinoid heart disease - the heart of the matter. Rev Endocr Metab Disord 2021;22:553-61. [PMID: 33443717 DOI: 10.1007/s11154-020-09624-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol 2020;5:850-61. [PMID: 32171056 DOI: 10.1016/S2468-1253(19)30414-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Luley K, Gebauer J, Gebauer N, Tharun L, Buchmann I, Barkhausen J, von Bubnoff N, Lindner K, Keck T, Lehnert H, Schmid SM. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research]. Internist (Berl). 2020;61:875-890. [PMID: 32676723 DOI: 10.1007/s00108-020-00832-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
5 Bader M. Inhibition of serotonin synthesis: A novel therapeutic paradigm. Pharmacol Ther 2020;205:107423. [PMID: 31629717 DOI: 10.1016/j.pharmthera.2019.107423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Clin Ther 2021;43:1779-85. [PMID: 34598813 DOI: 10.1016/j.clinthera.2021.08.014] [Reference Citation Analysis]